Stopped: insufficient funding
Gastroesophageal reflux disease (GERD) is a common chronic condition, affecting approximately 20% of the American adult population. Proton pump inhibitors (PPIs) are now the mainstay of medical therapy for symptoms of GERD. Despite their efficacy, several studies have shown that a significant proportion of GERD patients are either partial or non-responders to PPI therapy, defined as symptoms of heartburn and/or regurgitation not relieved by either a standard or double dose of a PPI during a minimum trial of 8 weeks. If GERD symptoms persist, further testing is required. This study will mirror the real world setting to assess the value of published guidelines which recommend specific testing and treatment.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Objectively evaluate PPI non-responder
Timeframe: 8 Weeks after visit 2
Esophageal acid exposure
Timeframe: 8 Weeks after visit 2
Response to different PPI
Timeframe: 8 Weeks after visit 2
Document the amount of esophageal acid and non-acid exposure in the PPI non-responder patient with proven GERD
Timeframe: 8 Weeks after visit 2
Determine the type, frequency and extent of esophageal motility disorders
Timeframe: 8 Weeks after visit 2
Nepean Dyspepsia Index
Timeframe: 8 Weeks after visit 2
Correlate subjective symptoms of GERD with objective evidence of acid reflux
Timeframe: 8 Weeks after visit 2
Assess overlapping symptoms of dysphagia and GERD
Timeframe: 8 Weeks after visit 2